The 30-day mortality rates among patients undergoing transcatheter aortic valve replacement (TAVR) have decreased by more than half over the last decade, with significant differences between genders, a CENTER* collaboration analysis has shown.
The antithrombotic potency of ticagrelor alone on ex vivo whole blood thrombogenicity does not differ from that of ticagrelor plus aspirin in high-risk patients who have undergone percutaneous coronary intervention (PCI), according to the thrombogenicity substudy of the TWILIGHT* trial.
In patients with high-bleeding risk, undergoing PCI* with a polymer-based drug-eluting stent (DES) was noninferior to a polymer-free drug-coated stent (DCS) when followed by a 1-month dual antiplatelet therapy (DAPT), according to the Onyx ONE** trial presented at TCT 2019.
In low-risk patients with severe aortic stenosis (AS), those treated with transcatheter aortic valve replacement (TAVR) had a significantly better disease-specific health status at 1 year compared with those who received surgical aortic valve replacement (SAVR), according to the PARTNER 3* trial presented at TCT 2019.
Subgroup analyses of the GLOBAL LEADERS study showed similar treatment effects between ticagrelor and aspirin monotherapy following percutaneous coronary intervention (PCI) in patients with impaired renal function (IRF)* and diabetes.
Shorter courses of dual antiplatelet therapy do not perform worse than longer regimens, according to a recent study presented at the 31st Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019).
Patients with severe aortic stenosis and intermediate surgical risk may benefit from either transcatheter (TAVR) or surgical aortic valve replacement (SAVR) through 5 years of follow-up, according to midterm data from the PARTNER 2A trial presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
The efficacy of transcatheter mitral-valve repair with the MitraClip device plus guideline-directed medical therapy (GDMT) over GDMT only in reducing hospitalizations for heart failure (HHF) among patients with HF and secondary mitral regurgitation (MR) was sustained at 3 years, including in patients who crossed over from GDMT alone at 2 years, updated results of the COAPT* trial show.